ArticleAnnals of clinical and translational neurology2026
Inebilizumab in AQP4-Seropositive NMOSD: One-Year Follow-Up From a Multicenter, Real-World Study.
Article in Annals of clinical and translational neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectiveReal-world evidence on inebilizumab among neuromyelitis optica spectrum disorder (NMOSD) patients is lacking. This study assessed inebilizumab among Chinese patients with aquaporin 4 autoantibody (AQP4-IgG)-seropositive NMOSD in a real-world setting.
methodsThis multicenter, prospective, observational study enrolled patients with AQP4-IgG-seropositive NMOSD who received at least one dose of inebilizumab. The primary outcome was the time to first adjudicated NMOSD attack.
resultsA total of 143 patients with AQP4-IgG-seropositive NMOSD were included. Over a median follow-up of 12.4 months (range: 0.4-25.4), five patients (3.50%) experienced attacks, with a 1-year cumulative incidence of 4.54% (95% confidence interval, 1.66-9.70). Annualized attack rate decreased from 1.02 to 0.03 after inebilizumab treatment, and the Expanded Disability Status Scale scores were significantly improved, with a median change of -0.50 (range, -5.0 to 1.5; p < 0.0001; worsening rate, 0.70%) at 1 year. The most common treatment-emergent adverse events were urinary tract infection (6.29%), and one case of pneumonia (0.70%) was reported as serious adverse event. B-cell depletion was effectively achieved, with only 1 patient reporting hypogammaglobulinemia.
conclusionInebilizumab demonstrated real-world effectiveness and a manageable safety profile in a diverse population of patients with AQP4-IgG-seropositive NMOSD, supporting the findings of the pivotal N-MOmentum trial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.